Cover Image
市場調查報告書

PharmaPoint:第二型糖尿病 - 全球醫藥品市場預測與市場分析

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 298049
出版日期 內容資訊 英文 476 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:第二型糖尿病 - 全球醫藥品市場預測與市場分析 PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年06月01日 內容資訊: 英文 476 Pages
簡介

主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本) 、新興國家 (中國、印度) 的第二型糖尿病的治療藥市場,預計從2015年的312億美元,到2025年擴大到587億美元。市場預計2015年∼2025年以6.5%的年複合成長率成長。

本報告提供第二型糖尿病的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因
  • 病理生理學
  • 預後
  • QOL
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
    • 中國、印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測
    • 確診的患者數
    • 確診的患者數 (各年齡)
    • 確診的患者數 (性別)
    • 確診的患者數 (年齡調整) 等
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Metformin
    • 磺醯尿素類,其他胰島素分泌促進藥
    • αGlucosidase抑制劑 (AGI)
    • 胰島素增敏劑 (TZD)
    • GLP-1受體激動劑
    • DPP-4抑制劑
    • SGLT-2抑制劑
    • 胰島素製劑

第7章 未滿足需求和機會

  • 概要
  • 提供永續的血糖管理的病理修飾療法
  • 血糖作用沒有的藥物
  • 副作用改善的藥物
  • 患者的藥物服用遵守增加

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的潛力藥物

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Eli Lilly
    • Novo Nordisk
    • Sanofi
    • GlaxoSmithKline
    • AstraZeneca
    • Merck & Co.
    • Boehringer Ingelheim
    • 武田藥品工業
    • Roche
    • Pfizer
    • Johnson & Johnson
    • Novartis
    • Intarcia Therapeutics

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC128PIDR

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.

Highlights

Key Questions Answered

  • Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market?
  • The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1RAs, DPP-4Is, and SGLT-2Is. Despite this, an oral GLP-1RA formulation and an osmotic pump which delivers subcutaneous exenatide for one year at a time are expected to be game changers in the GLP-1RA class. Both are in Phase III clinical trials and are expected to increase compliance among T2D patients. Will the late-stage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Key Findings

  • The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
  • The second largest driver will be the physicians' efforts to delay disease progression through the use of combination therapies and novel branded drugs.
  • With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs.
  • In the future, companies will have to shift their focus towards competitive pricing, "niche" drugs aimed at smaller patient groups, and drugs that increase patient compliance (through more convenient administration).
  • To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.

Scope

  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global T2D therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology
  • 3.2. Pathophysiology
  • 3.3. Prognosis
  • 3.4. Quality of Life
  • 3.5. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. China and India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used for Diagnosed Prevalence of T2D
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D
  • 4.5. Epidemiological Forecast for T2D (2015-2025)
    • 4.5.1. Diagnosed Prevalent Cases of T2D
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of T2D
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of T2D
    • 4.5.4. Age-Standardized Diagnosed Prevalence of T2D
    • 4.5.5. Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases
    • 4.5.6. Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases
    • 4.5.7. Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases
    • 4.5.8. Prevalent Cases of Hypertension Among Diagnosed T2D Cases
    • 4.5.9. Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
    • 5.1.1. Diagnosis and Referrals
    • 5.1.2. Treatment Guidelines and Leading Prescribed Therapies
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. China
  • 5.10. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Metformin
    • 6.3.2. Sulfonylureas and Other Insulin Secretagogues
    • 6.3.3. α-glucosidase Inhibitors
    • 6.3.4. Thiazolidinediones
    • 6.3.5. Glucagon-Like Peptide-1KKKKK Receptor Agonists
    • 6.3.6. Dipeptidyl-Peptidase 4KKKKK Inhibitors
    • 6.3.7. Sodium-Glucose Cotransporter 2KKKKK Inhibitors
    • 6.3.8. Insulin Formulations

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. Disease-Modifying Treatments Providing Sustained Glycemic Control
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Drugs with Non-Glycemic Benefits
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Drugs with Improved Side-Effect Profiles
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Increased Patient Compliance
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
    • 8.2.2. Clinical Trials by Phase and Trial Status
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Semaglutide
    • 8.3.2. OG217SC/Semaglutide (oral)
    • 8.3.3. ITCA 650
    • 8.3.4. Marizev (omarigliptin)
    • 8.3.5. Ertugliflozin
    • 8.3.6. FIAsp
    • 8.3.7. Biosimilar Insulins

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Eli Lilly
    • 9.3.2. Novo Nordisk
    • 9.3.3. Sanofi
    • 9.3.4. GlaxoSmithKline
    • 9.3.5. AstraZeneca
    • 9.3.6. Merck & Co.
    • 9.3.7. Boehringer Ingelheim
    • 9.3.8. Takeda
    • 9.3.9. Roche
    • 9.3.10. Pfizer
    • 9.3.11. Johnson & Johnson
    • 9.3.12. Novartis
    • 9.3.13. Intarcia Therapeutics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. India
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed T2D Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst - CVMD
    • 11.6.2. Director - CVMD
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Director of Therapy Analysis and Epidemiology
    • 11.6.5. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: T2D Pathophysiology
  • Table 2: Symptoms of T2D
  • Table 3: Risk Factors and Comorbidities for T2D
  • Table 4: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D
  • Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D
  • Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D
  • Table 7: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D
  • Table 8: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D
  • Table 9: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D
  • Table 10: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Table 11: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015
  • Table 12: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N (Row %), 2015
  • Table 13: Diagnostic Tests and Typical Criteria for T2D
  • Table 14: T2D Treatments
  • Table 15: Country Profile, T2D Management - US
  • Table 16: Country Profile, T2D Management - France
  • Table 17: Country Profile, T2D Management - Germany
  • Table 18: Country Profile, T2D Management - Italy
  • Table 19: Country Profile, T2D Management - Spain
  • Table 20: Country Profile, T2D Management - UK
  • Table 21: Country Profile, T2D Management - Japan
  • Table 22: Country Profile, T2D Management - China
  • Table 23: Country Profile, T2D Management - India
  • Table 24: Leading Branded Treatments for T2D, 2015
  • Table 25: Product Profile - Metformin
  • Table 26: Metformin SWOT Analysis, 2015
  • Table 27: Global Sales Forecasts ($M) for Metformin, 2015-2025
  • Table 28: First-Generation SUs
  • Table 29: Second-Generation SUs
  • Table 30: Product Profile - SUs
  • Table 31: SUs SWOT Analysis, 2015
  • Table 32: Global Sales Forecasts ($M) for SUs and non-SUs, 2015-2025
  • Table 33: Product Profile - Acarbose
  • Table 34: AGIs SWOT Analysis, 2015
  • Table 35: Global Sales Forecasts ($M) for AGIs, 2015-2025
  • Table 36: Product Profile - Actos
  • Table 37: TZDs SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($M) for TZDs, 2015-2025
  • Table 39: GLP-1RAs
  • Table 40: Product Profile - Byetta
  • Table 41: Byetta SWOT Analysis, 2015
  • Table 42: Global Sales Forecasts ($M) for Byetta, 2015-2025
  • Table 43: Product Profile - Victoza
  • Table 44: Victoza SWOT Analysis, 2015
  • Table 45: Global Sales Forecasts ($M) for Victoza, 2015-2025
  • Table 46: Product Profile - Bydureon
  • Table 47: Bydureon SWOT Analysis, 2015
  • Table 48: Global Sales Forecasts ($M) for Bydureon, 2015-2025
  • Table 49: Product Profile - Lyxumia
  • Table 50: Lyxumia SWOT Analysis, 2015
  • Table 51: Global Sales Forecasts ($M) for Lyxumia, 2015-2025
  • Table 52: Product Profile - Tanzeum
  • Table 53: Tanzeum SWOT Analysis, 2015
  • Table 54: Global Sales Forecasts ($M) for Tanzeum, 2015-2025
  • Table 55: Product Profile - Trulicity
  • Table 56: Trulicity SWOT Analysis, 2015
  • Table 57: Global Sales Forecasts ($M) for Trulicity, 2015-2025
  • Table 58: Marketed DPP-4Is
  • Table 59: Marketed DPP-4Is in Combination with Other OADs
  • Table 60: Product Profile - Januvia
  • Table 61: Januvia SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($M) for Januvia, Janumet, Janumet XR, 2015-2025
  • Table 63: Product Profile - Onglyza
  • Table 64: Onglyza SWOT Analysis, 2015
  • Table 65: Global Sales Forecasts ($M) for Onglyza, Kombiglyze, XR, 2015-2025
  • Table 66: Product Profile - Tradjenta
  • Table 67: Tradjenta SWOT Analysis, 2015
  • Table 68: Global Sales Forecasts ($M) for Tradjenta, Jentadueto, 2015-2025
  • Table 69: Product Profile - Galvus
  • Table 70: Galvus SWOT Analysis, 2015
  • Table 71: Global Sales Forecasts ($M) for Galvus, Eucreas, 2015-2025
  • Table 72: Product Profile - Nesina
  • Table 73: Nesina SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($M) for Nesina, Oseni, Kazano, 2015-2025
  • Table 75: Product Profile - Tenelia
  • Table 76: Tenelia SWOT Analysis, 2015
  • Table 77: Global Sales Forecasts ($M) for Tenelia, 2015-2025
  • Table 78: Product Profile - Suiny
  • Table 79: Suiny SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($M) for Suiny, 2015-2025
  • Table 81: Product Profile - Zafatek
  • Table 82: Zafatek SWOT Analysis, 2015
  • Table 83: Global Sales Forecasts ($M) for Zafatek, 2015-2025
  • Table 84: SGLT-2Is
  • Table 85: Marketed SGLT-2Is in Combination with Other T2D Drugs
  • Table 86: Product Profile - Forxiga
  • Table 87: Forxiga SWOT Analysis, 2015
  • Table 88: Global Sales Forecasts ($M) for Forxiga, Xigduo XR, SaxaDapa, SaxaDapa + metformin, 2015-2025
  • Table 89: Product Profile - Invokana
  • Table 90: Invokana SWOT Analysis, 2015
  • Table 91: Global Sales Forecasts ($M) for Invokana, InvokaMet, XR, IR, 2015-2025
  • Table 92: Product Profile - Jardiance
  • Table 93: Jardiance SWOT Analysis, 2015
  • Table 94: Global Sales Forecasts ($M) for Jardiance, Synjardy, Glyxambi, 2015-2025
  • Table 95: Product Profile - Apleway
  • Table 96: Apleway SWOT Analysis, 2015
  • Table 97: Global Sales Forecasts ($M) for Apleway, 2015-2025
  • Table 98: Product Profile - Suglat
  • Table 99: Suglat SWOT Analysis, 2015
  • Table 100: Global Sales Forecasts ($M) for Suglat, 2015-2025
  • Table 101: Product Profile - Lusefi
  • Table 102: Lusefi SWOT Analysis, 2015
  • Table 103: Global Sales Forecasts ($m) for Lusefi, 2015-2025
  • Table 104: Insulins - Overview and Comparison
  • Table 105: Insulin Formulations
  • Table 106: Product Profile - Humalog
  • Table 107: Humalog SWOT Analysis, 2015
  • Table 108: Global Sales Forecasts ($M) for Humalog, Humalog Mixes, Humalog 200U, 2015-2025
  • Table 109: Product Profile - Lantus
  • Table 110: Lantus SWOT Analysis, 2015
  • Table 111: Global Sales Forecasts ($M) for Lantus, Toujeo LixiLan, 2015-2025
  • Table 112: Toujeo SWOT Analysis, 2015
  • Table 113: Product Profile - Levemir
  • Table 114: Levemir SWOT Analysis, 2015
  • Table 115: Global Sales Forecasts ($M) for Levemir, 2015-2025
  • Table 116: Product Profile - NovoLog
  • Table 117: NovoLog SWOT Analysis, 2015
  • Table 118: Global Sales Forecasts ($M) for NovoRapid, NovoMix, FIAsp, 2015-2025
  • Table 119: Product Profile - Apidra
  • Table 120: Apidra SWOT Analysis, 2015
  • Table 121: Global Sales Forecasts ($M) for Apidra, 2015-2025
  • Table 122: Product Profile - Tresiba
  • Table 123: Tresiba SWOT Analysis, 2015
  • Table 124: Global Sales Forecasts ($M) for Tresiba, Xultophy, Ryzodeg, 2015-2025
  • Table 125: Product Profile - Afrezza
  • Table 126: Afrezza SWOT Analysis, 2015
  • Table 127: Global Sales Forecasts ($M) for Afrezza, 2015-2025
  • Table 128: Unmet Needs and Opportunities in T2D
  • Table 129: T2D - Clinical Trials by Phase and Status, 2015
  • Table 130: T2D - Phase Pipeline, 2015
  • Table 131: Comparison of Therapeutic Classes in Development for T2D, 2015
  • Table 132: Product Profile - Semaglutide
  • Table 133: Semaglutide SWOT Analysis, 2015
  • Table 134: Global Sales Forecasts ($M) for Semaglutide, 2015-2025
  • Table 135: Product Profile - OG217SC
  • Table 136: OG217SC SWOT Analysis, 2015
  • Table 137: Global Sales Forecasts ($M) for OG217SC, 2015-2025
  • Table 138: Product Profile - ITCA 650
  • Table 139: ITCA-650 SWOT Analysis, 2015
  • Table 140: Global Sales Forecasts ($M) for ITCA-650, 2015-2025
  • Table 141: Product Profile - Marizev
  • Table 142: Marizev SWOT Analysis, 2015
  • Table 143: Global Sales Forecasts ($M) for Marizev, 2015-2025
  • Table 144: Product Profile - Ertugliflozin
  • Table 145: Ertugliflozin SWOT Analysis, 2015
  • Table 146: Global Sales Forecasts ($M) for Ertugliflozin, Ertugliflozin + metformin, Sitagliptin + Ertugliflozin, 2015-2025
  • Table 147: Product Profile - FIAsp
  • Table 148: FIAsp SWOT Analysis, 2015
  • Table 149: Product Profile - Abasaglar
  • Table 150: Abasaglar SWOT Analysis, 2015
  • Table 151: Global Sales Forecasts ($M) for Abasaglar, 2015-2025
  • Table 152: Key Companies in the T2D Market, 2015
  • Table 153: Other Companies in the T2D Market, 2015
  • Table 154: Eli Lilly's T2D Portfolio Assessment, 2015
  • Table 155: Eli Lilly SWOT Analysis, 2015
  • Table 156: Novo Nordisk's T2D Portfolio Assessment, 2015
  • Table 157: Novo Nordisk SWOT Analysis, 2015
  • Table 158: Sanofi's T2D Portfolio Assessment, 2015
  • Table 159: Sanofi SWOT Analysis, 2015
  • Table 160: GSK's T2D Portfolio Assessment, 2015
  • Table 161: GSK SWOT Analysis, 2015
  • Table 162: AstraZeneca's T2D Portfolio Assessment, 2015
  • Table 163: AstraZeneca SWOT Analysis, 2015
  • Table 164: Merck's T2D Portfolio Assessment, 2015
  • Table 165: Merck SWOT Analysis, 2015
  • Table 166: BI's T2D Portfolio Assessment, 2015
  • Table 167: BI SWOT Analysis, 2015
  • Table 168: Takeda's T2D Portfolio Assessment, 2015
  • Table 169: Takeda SWOT Analysis, 2015
  • Table 170: Roche's T2D Portfolio Assessment, 2015
  • Table 171: Roche SWOT Analysis, 2015
  • Table 172: Pfizer's T2D Portfolio Assessment, 2015
  • Table 173: Pfizer SWOT Analysis, 2015
  • Table 174: J&J's T2D Portfolio Assessment, 2015
  • Table 175: J&J SWOT Analysis, 2015
  • Table 176: Novartis' T2D Portfolio Assessment, 2015
  • Table 177: Novartis SWOT Analysis, 2015
  • Table 178: Intarcia Therapeutics' T2D Portfolio Assessment, 2015
  • Table 179: Intarcia Therapeutics SWOT Analysis, 2015
  • Table 180: Global Sales Forecasts ($M) for T2D, 2015-2025
  • Table 181: T2D Market - Drivers and Barriers, 2015
  • Table 182: Sales Forecasts ($M) for T2D in the US, 2015-2025
  • Table 183: Key Events Impacting Sales for T2D in the US, 2015-2025
  • Table 184: T2D Market - Drivers and Barriers in the US, 2015
  • Table 185: Sales Forecasts ($M) for T2D in France, 2015-2025
  • Table 186: Key Events Impacting Sales for T2D in France, 2015-2025
  • Table 187: T2D Market - Drivers and Barriers in France, 2015
  • Table 188: Sales Forecasts ($M) for T2D in Germany, 2015-2025
  • Table 189: Key Events Impacting Sales for T2D in Germany, 2015-2025
  • Table 190: T2D Market - Drivers and Barriers in Germany, 2015
  • Table 191: Sales Forecasts ($M) for T2D in Italy, 2015-2025
  • Table 192: Key Events Impacting Sales for T2D in Italy, 2015-2025
  • Table 193: T2D Market - Drivers and Barriers in Italy, 2015
  • Table 194: Sales Forecasts ($M) for T2D in Spain, 2015-2025
  • Table 195: Key Events Impacting Sales for T2D in Spain, 2015-2025
  • Table 196: T2D Market - Drivers and Barriers in Spain, 2015
  • Table 197: Sales Forecasts ($M) for T2D in the UK, 2015-2025
  • Table 198: Key Events Impacting Sales for T2D in the UK, 2015-2025
  • Table 199: T2D Market - Drivers and Barriers in the UK, 2015
  • Table 200: Sales Forecasts ($M) for T2D in Japan, 2015-2025
  • Table 201: Key Events Impacting Sales for T2D in Japan, 2015-2025
  • Table 202: T2D Market - Drivers and Barriers in Japan, 2015
  • Table 203: Sales Forecasts ($M) for T2D in China, 2015-2025
  • Table 204: Key Events Impacting Sales for T2D in China, 2015-2025
  • Table 205: T2D Market - Drivers and Barriers in China, 2015
  • Table 206: Sales Forecasts ($M) for T2D in India, 2015-2025
  • Table 207: Key Events Impacting Sales for T2D in India, 2015-2025
  • Table 208: T2D Market - Drivers and Barriers in India, 2015
  • Table 209: Key Launch Dates
  • Table 210: Key Patent Expiries
  • Table 211: Number of High-Prescribing Physicians Surveyed

List of Figures

  • Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015
  • Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2015
  • Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages ≥20 Years, by Sex, 2015
  • Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages ≥20Years, N, 2015
  • Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 10: Incretin and SGLT-2I Mechanisms of Action
  • Figure 11: ADA/EASD General Recommendations for Antihyperglycemic Therapy
  • Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2015-2025
  • Figure 13: Company Portfolio Gap Analysis in T2D, 2015-2025
  • Figure 14: 9MM, Global Sales for T2D by Region, 2015-2025
  • Figure 15: Sales for T2D in the US by Drug Class, 2015-2025
  • Figure 16: Sales for T2D in France by Drug Class, 2015-2025
  • Figure 17: Sales for T2D in Germany by Drug Class, 2015-2025
  • Figure 18: Sales for T2D in Italy by Drug Class, 2015-2025
  • Figure 19: Sales for T2D in Spain by Drug Class, 2015-2025
  • Figure 20: Sales for T2D in the UK by Drug Class, 2015-2025
  • Figure 21: Sales for T2D in Japan by Drug Class, 2015-2025
  • Figure 22: Sales for T2D in China by Drug Class, 2015-2025
  • Figure 23: Sales for T2D in India by Drug Class, 2015-2025
Back to Top